Detlef K. Bartsch

Detlef K. Bartsch


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2012 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
DBDetlef K. Bartsch
Detlef K. Bartsch
TGThomas M Gress
Thomas M Gress
PLPeter Langer
Peter Langer

1 October 2014 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
GDGuido Di Dalmazi
Guido Di Dalmazi
CKCaroline Kisker
Caroline Kisker
DCDavide Calebiro
Davide Calebiro
MMMassimo Mannelli,
Massimo Mannelli,
Letizia CanuLetizia Canu
Letizia Canu
MPMartin Reincke Prof
Martin Reincke Prof
Context: Somatic mutations in PRKACA gene, encoding the catalytic subunit of protein kinase A (PKA), have been recently found in a high proportion of sporadic adenomas associated with Cushing's syndrome. The aim was to analyze the PRKACA mutation in a large cohort of patients with adrenocortical masses. Methods: Samples from nine European centers were included (Germany, n = 4; Italy, n = 4; France, n = 1). Samples were drawn from 149 patients with nonsecreting adenomas (n = 32 + 2 peritumoral), subclinical hypercortisolism (n = 36), Cushing's syndrome (n = 64 + 2 peritumoral), androgen-producing tumors (n = 4), adrenocortical carcinomas (n = 5 + 2 peritumoral), and primary bilateral macronodular adrenal hyperplasias (n = 8). Blood samples were available from patients with nonsecreting adenomas (n = 15), subclinical hypercortisolism (n = 10), and Cushing's syndrome (n = 35). Clinical and hormonal data were collected. DNA amplification by PCR of exons 6 and 7 of the PRKACA gene and direct sequencing were performed. Results: PRKACA heterozygous mutations were found in 22/64 samples of Cushing's syndrome patients (34%). No mutations were found in peritumoral tissue and blood samples or in other tumors examined. The c.617A>C (p.Leu206Arg) occurred in 18/22 patients. Furthermore, two novel mutations were identified: c.600_601insGTG/p.Cys200_Gly201insVal in three patients and c.639C>G+c.638_640insATTATCCTGAGG/p.Ser213Arg+p.Leu212_Lys214insIle-Ile-Leu-Arg) in one. All the mutations involved a region implicated in interaction between PKA regulatory and catalytic subunits. Patients with somatic PRKACA mutations showed higher levels of cortisol after dexamethasone test and a smaller adenoma size, compared with nonmutated subjects. Conclusions: These data confirm and extend previous observations that somatic PRKACA mutations are specific for adrenocortical adenomas causing Cushing's syndrome.

2 October 2015 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
KLKerstin Lorenz
Kerstin Lorenz
DBDetlef K. Bartsch
Detlef K. Bartsch
JSJuan J. Sancho
Juan J. Sancho
SGSebastien Guigard
Sebastien Guigard
FTFrederic Triponez
Frederic Triponez

1 February 2013 in Annals of Surgery
Verified
Journal Article
Closed access
CLCaroline L. Lopez
Caroline L. Lopez
MFMassimo Falconi
Massimo Falconi
JWJens Waldmann
Jens Waldmann
LBLetizia Boninsegna
Letizia Boninsegna
VFVolker Fendrich
Volker Fendrich
DBDetlef K. Bartsch
Detlef K. Bartsch
Objective: To evaluate the outcome of pancreaticoduodenectomy (PD) versus non-PD resections for the treatment of gastrinoma in multiple endocrine neoplasia type 1. Background: Gastrinoma in MEN1 is considered a rarely curable disease and its management is highly controversial both for timing and extent of surgery. Methods: Clinical characteristics, complications and outcomes of 27 prospectively collected MEN1 patients with biochemically proven gastrinoma, who underwent surgery, were analyzed with special regard to the gastrinoma type and the initial operative procedure. Results: Twenty-two (81%) patients with gastrinoma in MEN1 had duodenal gastrinomas and 5 patients (19%) had pancreatic gastrinomas. At the time of diagnosis, 21 (77%) gastrinomas were malignant (18 duodenal, 3 pancreatic), but distant metastases were only present in 4 (15%) patients. Patients with pancreatic gastrinomas underwent either distal pancreatic resections or gastrinoma enucleation with lymphadenectomy, 2 patients also had synchronous resections of liver metastases. One of these patients was biochemically cured after a median of 136 (77–312) months. Thirteen patients with duodenal gastrinomas underwent PD resections (group 1, partial PD [n = 11], total PD [n = 2]), whereas 9 patients had no-PD resections (group 2) as initial operative procedure. Perioperative morbidity and mortality, including postoperative diabetes, differed not significantly between groups (P > 0.5). All patients of group 1 and 5 of 9 (55%) patients of group 2 had a negative secretin test at hospital discharge. However, after a median follow-up of 136 (3–276) months, 12 (92%) patients of group 1 were still normogastrinemic compared to only 3 of 9 (33%) patients of group 2 (P = 0.023). Three (33%) patients of group 2 had to undergo up to 3 reoperations for recurrent or metastatic disease compared to none of group 1. Conclusions: Duodenal gastrinoma in MEN1 should be considered a surgically curable disease. PD seems to be the adequate approach to this disease, providing a high cure rate and acceptable morbidity compared to non-PD resections.

Verified
Journal Article
Open access
PDF file
DBDetlef K. Bartsch
Detlef K. Bartsch
CDCornelia Dotzenrath
Cornelia Dotzenrath
CVChristian Vorländer
Christian Vorländer
AZAndreas Zielke
Andreas Zielke
TWTheresia Weber
Theresia Weber
TGthe StuDoQ/Thyroid Study Group
the StuDoQ/Thyroid Study Group
Background: To evaluate the current indications, resection strategies and short-term outcomes of surgery for benign goitre in a country with endemic goitre. Methods: Data of patients who underwent surgery for benign goitre were retrieved from the prospective StuDoQ/Thyroid registry and retrospectively analysed regarding the patient’s demographics, indications for surgery, surgical procedures, histology, and perioperative outcomes. Results: In a 15-month period, 12,888 patients from 83 departments underwent thyroid resections for benign conditions. Main indications for surgery were exclusion of malignancy (68%), compression symptoms (20.7%) and hyperthyroidism (9.7%). Preoperative fine needle aspiration cytology was performed in only 12.2% of patients with the indication “exclusion of malignancy”. Thyroidectomy (49.8%) or hemithyroidectomy (36.9%) were performed in 86.7% of patients. Minimally invasive or alternative surgical techniques were applied in only 2.2%. Intraoperative neuromonitoring was used in 98.4% of procedures, in 97.5% of patients at least one parathyroid gland was visualized, and in 15.3% of patients parathyroid tissue was autografted, respectively. The rates of unilateral and bilateral transient recurrent nerve palsy were 3.6% and 0.07% of nerves at risk, the rate of transitory hypoparathyroidism was 15.3%. The rates of postoperative bleeding and wound infections requiring reoperation were 1.4% and 0.07%, respectively. Conclusions: The indication “exclusion of malignancy” is made too liberally, and there is a strong attitude to perform complete thyroid resections. Postoperative hypoparathyroidism is the major complication after surgery for benign thyroid disease, thus requiring more awareness.

22 November 2012 in Familial Cancer
Verified
Journal Article
Closed access
PDF file
DBDetlef K. Bartsch
Detlef K. Bartsch
KDK. Dietzel
K. Dietzel
MBM. Bargello
M. Bargello
EME. Matthaei
E. Matthaei
GKG. Kloeppel
G. Kloeppel
PLP. Langer
P. Langer